Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $141,494.34 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,666 shares of Xeris Biopharma stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $8.49, for a total value of $141,494.34. Following the sale, the insider directly owned 1,127,796 shares in the company, valued at $9,574,988.04. This trade represents a 1.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Monday, August 3rd, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.01, for a total value of $133,494.66.
• On Wednesday, July 1st, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.03, for a total value of $133,827.98.

Xeris Biopharma Price Performance

XERS traded down $0.01 during trading on Tuesday, reaching $8.43. 1,144,088 shares of the company traded hands, compared to its average volume of 1,849,041. The company has a market cap of $1.54 billion, a P/E ratio of -76.64 and a beta of 0.66. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45. Xeris Biopharma Holdings, Inc. has a 12-month low of $5.25 and a 12-month high of $10.08. The firm has a fifty day simple moving average of $8.32 and a 200 day simple moving average of $6.93.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%.The company had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million. On average, equities analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.

Institutional Investors Weigh In On Xeris Biopharma

Large investors have recently bought and sold shares of the business. Cetera Investment Advisers raised its stake in Xeris Biopharma by 3.9% during the second quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock valued at $216,000 after purchasing an additional 1,735 shares in the last quarter. Royal Bank of Canada lifted its position in Xeris Biopharma by 6.5% during the fourth quarter. Royal Bank of Canada now owns 38,636 shares of the company’s stock valued at $304,000 after purchasing an additional 2,351 shares during the last quarter. AlphaCentric Advisors LLC grew its stake in shares of Xeris Biopharma by 5.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 45,886 shares of the company’s stock worth $266,000 after buying an additional 2,494 shares in the last quarter. Kestra Advisory Services LLC purchased a new position in shares of Xeris Biopharma in the 4th quarter worth $25,000. Finally, ProShare Advisors LLC increased its holdings in shares of Xeris Biopharma by 10.6% in the 4th quarter. ProShare Advisors LLC now owns 35,390 shares of the company’s stock worth $278,000 after buying an additional 3,383 shares during the last quarter. Institutional investors own 42.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on XERS. Wall Street Zen cut shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, Barclays boosted their target price on Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $12.00.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.